Healing Before Birth: How Genetic Screening Is Changing Lives
Advances in modern medicine allow us to treat fetuses and newborn babies for genetic or inherited diseases. Recent studies have expanded this capability from a small handful of conditions detected via heel stick tests to hundreds. A recent American Journal of Human Genetics study lists nearly 300 treatable fetal findings of actionable diseases.
Public health experts recognize the long-term advantages of investing in genetic screening. Approximately 12,500 infants each year—children who might otherwise face severe disability or even death—are identified and given a chance at a healthier life. Genetic screening is universally beneficial and incredibly effective. This progress, however, starkly contrasts the limited options of the past.
Modern prenatal screening employs non-invasive techniques to assess genetic risks in fetal development, enabling early detection of chromosomal conditions like Down syndrome and Trisomy 18, often in the first trimester. By analyzing fetal DNA fragments in a mother's blood, this method identifies potential genetic abnormalities and is safer than amniocentesis.
For postnatal screening, the heel stick test has been the standard method for newborn screening for decades. It is performed 24 to 48 hours after birth and involves pricking a baby's heel to collect a blood sample, which is analyzed for metabolic, hormonal, and genetic disorders. This test is crucial for identifying conditions like hypothyroidism, phenylketonuria, and sickle cell disease, which may not present symptoms at birth but can lead to serious complications if untreated. By 2024, this heel prick test will have become as routine as a lullaby in 48 states and Washington, D.C., safeguarding 98% of newborns in the United States.
While postnatal screening is essential, there is an increasing focus on empowering families with actionable insights even before birth. This includes providing a targeted list of treatable genetic disorders to guide pregnancy management, allowing for more effective gene therapy during fetal development when stem cells are more adaptable than post-birth treatments.
The actionable interventions for the newly detectable conditions fall into several distinct categories, each offering transformative potential. Collectively, these treatments address immediate health concerns, dramatically enhance the quality of life and extend longevity for affected individuals.
Gene therapy, including CRISPR and viral vectors, can correct genes responsible for specific conditions. Advanced delivery methods, such as nano-carriers, allow targeted therapy to fetal cells, improving effectiveness and minimizing complications compared to postnatal treatments. Early intervention can prevent permanent damage, with prenatal therapies showing success for conditions like spinal muscular atrophy. The emergence of FDA-approved gene therapies for beta-thalassemia and inherited blindness highlights the field's progress, with over 800 gene therapy programs worldwide improving patient outcomes.
Effective medication management is crucial for addressing metabolic disorders identified through early screening. This process involves selecting and administering specific medications and dietary adjustments tailored to each individual's needs. These measures help alleviate symptoms and prevent long-term complications.
Surgical interventions play a vital role in correcting congenital heart defects detected during infancy or childhood. When performed promptly, these surgeries can significantly improve long-term outcomes and enhance the quality of life for affected individuals.
Immunotherapy, including bone marrow transplants and gene therapy, is essential for managing immune deficiencies such as severe combined immunodeficiency. Early diagnosis and intervention can save lives, restore immune function and enable individuals to participate more fully in their communities.
The ability to diagnose and treat nearly 300 actionable genetic conditions in fetuses and newborns marks a significant milestone in modern medicine. From traditional heel stick tests to cutting-edge genomic sequencing, these advances empower families with critical information and life-saving options. As research continues to evolve, integrating these technologies into routine prenatal and neonatal care promises to redefine pediatric healthcare, offering hope for conditions once deemed untreatable.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
4 hours ago
- Yahoo
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
USA Today
6 hours ago
- USA Today
The advice you're missing about your pre-workout
Whether you're rolling out of bed at dawn, sacrificing your lunch break for gym time or syncing schedules with a motivated friend to squeeze in an evening workout, the goal is usually about making the most out of every rep, step and minute. While buying better gear, using fitness apps or hiring a personal trainer can all help, a growing number of gym goers are chasing an extra edge through supplementary pills, powders or liquids known as pre-workouts. But do these products really deliver? Here's what they are, which ingredients to watch for and what else you can do beyond supplementation to get the most out of every sweat session. What are pre-workouts? Pre-workouts are dietary supplements designed to reduce muscle fatigue and boost energy, focus, endurance and performance during exercise. Typically taken 20 to 30 minutes before training, they contain a variety of ingredients intended to prime both body and brain for more intense physical effort. Caffeine is the most common and potent ingredient in many of these products because it's a well-established stimulant that enhances alertness and reduces fatigue, at least in the short term. Most pre-workouts contain 150 to 300 milligrams (roughly the amount in 1 to 3 cups of coffee), though some provide even higher (and sometimes unsafe) doses. And while a caffeine boost helps some people, others react poorly. 'Caffeine is not for everyone,' says Bonnie Taub-Dix, a registered dietitian nutritionist and author of "Read It Before You Eat It – Taking You from Label to Table." For some, she says, "caffeine makes them feel jittery or causes an upset stomach." Beyond caffeine, other common ingredients offered in pre-workout supplements include beta-alanine and creatine, plus minerals like zinc and magnesium. Great question: What is magnesium good for? What's the best pre-workout? There's no one-size-fits-all formula since the best pre-workout supplements always depend on one's body, goals and tolerance to certain ingredients. "It's about finding what works for each individual," says Dr. Danielle Ponzio, an orthopedic surgeon who frequently treats athletes at Thomas Jefferson University Hospital in Philadelphia. Ingredients like beta-alanine and creatine are among the most well-researched and effective when properly dosed. No matter which ingredients you're eyeing, label literacy is key. 'Be sure to check labels and look for third-party tested brands to ensure safety and effectiveness,' advises Taub-Dix. That's crucial, since dietary supplements are not regulated by the U.S. Food & Drug Administration (FDA) the way food or medicine are. You'll also want to assess factors like cost, brand reputation, ingredient sourcing and overall quality in any pre-workouts you're considering. And don't overdo it with any ingredient, of course, but be especially cautious when it comes to stimulants. 'Consider how much caffeine you're actually consuming each day across all caffeinated beverages you're drinking and any supplements you're taking,' stresses Taub-Dix. The FDA recommends drinking no more than 400 milligrams daily. It's also wise to steer clear of pre-workout products with "proprietary" blends (which often obscure ingredient amounts), untested stimulants or artificial additives, as they can carry unnecessary risks. Heads up: TikTok Shop is full of supplements for sale. Nutrition experts warn to 'tread carefully.' What's the best way to prepare for a workout? Indeed, nutrition is critical for optimizing performance, regardless of which supplements you add to your diet. 'Your overall nutrition plays the most crucial role in maximizing workout performance and recovery,' says Ponzio. For example, eating a meal or snack high in carbohydrates and moderate in protein one to four hours before exercising can fuel your workout and 'optimize glycogen stores and maintain blood glucose levels,' she explains. Some balanced pre-workout snacks include Greek yogurt with fruit and nuts, oatmeal with almond butter or a smoothie made with yogurt, berries and greens, Taub-Dix says. And she cautions against relying on sugary foods or drinks, which provide only short bursts of energy and may cause digestive discomfort or sugar crashes. Similarly, consuming too much fiber right before exercise "can lead to bloating or sluggishness." Hydration is also key as replacing fluids lost through perspiration helps keep workouts safe and more effective. In the end, the most effective workout prep combines supplements (when needed), nutrition, movement and consistency, habits that pay off both before and after exercise. 'Post-exercise nutrition is also crucial,' says Ponzio. 'It can replenish glycogen stores, repair muscle tissue and rehydrate.'
